Imugene (#ASX: $IMU) has received a second Human Research Ethics Committee (HREC) approval to commence a Phase I clinical trial of its checkpoint immunotherapy candidate, PD1- Vaxx in Australia. https://t.co/Gu0pPW2eyH. #Immunity #clinicaltrials #biotech #pharmaceuticals #stocks https://t.co/59RRyvnvr4